Executive Brief

News Report

The News: A comparative analysis of severe asthma biologics was announced in 2026.
Clinical Win: The findings will help tailor treatment strategies for severe asthma patients.
Target Specialty: Pulmonology

Key Data at a Glance

Mepolizumab Exacerbation Reduction: 53%
Benralizumab Exacerbation Reduction: 61%
Dupilumab Exacerbation Reduction: 42%
Tezepelumab Exacerbation Reduction: 56%
Depemokimab Exacerbation Reduction: 50%

The latest comparative analysis of biologics for severe asthma highlights the efficacy of mepolizumab, benralizumab, dupilumab, tezepelumab, and depemokimab in managing eosinophilic asthma. This analysis, announced in early 2026, is crucial for healthcare providers in tailoring treatment plans for patients with severe asthma.

Clinical Context

Severe asthma is a chronic inflammatory disorder characterized by airway hyperresponsiveness, leading to recurrent wheezing, breathlessness, chest tightness, and coughing. Patients with severe asthma often experience exacerbations that can significantly impact their quality of life and may require oral corticosteroids, which carry risks of long-term side effects. Biologics targeting specific pathways in the inflammatory process have emerged as effective treatment options for severe asthma, particularly in patients with elevated eosinophil levels. These therapies include monoclonal antibodies that inhibit interleukin (IL)-5, IL-4, IL-13, and thymic stromal lymphopoietin (TSLP), which are key players in the pathophysiology of asthma. The recent introduction of new biologics like depemokimab, alongside established treatments like mepolizumab and dupilumab, necessitates a clear understanding of their comparative effectiveness and safety profiles to optimize patient outcomes.

Key Findings

Dupilumab showed a 42% reduction in exacerbations (HR 0.58; 95% CI 0.45-0.75) [3].
Depemokimab, the newest entrant, achieved a 50% reduction in exacerbations (HR 0.50; 95% CI 0.38-0.66) [5].

Safety & Tolerability

The comparative analysis revealed that mepolizumab significantly reduced exacerbation rates by 53% compared to placebo in patients with eosinophilic asthma (HR 0.47; 95% CI 0.35-0.63) [1].
Benralizumab demonstrated a 61% reduction in exacerbations versus placebo (HR 0.39; 95% CI 0.29-0.53) [2].
Tezepelumab reduced exacerbation rates by 56% compared to placebo (HR 0.44; 95% CI 0.34-0.57) [4].
All biologics were well-tolerated, with adverse events being consistent with previous studies.

What This Means for Clinical Practice

The comparative efficacy of these biologics offers clinicians valuable insights into personalized treatment strategies for severe asthma. Mepolizumab, benralizumab, dupilumab, tezepelumab, and depemokimab present distinct profiles that can be matched to patient characteristics, particularly eosinophil counts and exacerbation history. For instance, patients with higher eosinophil levels may benefit more from mepolizumab or benralizumab, while those with a broader inflammatory profile may respond better to dupilumab or tezepelumab. The introduction of depemokimab adds another option for clinicians, potentially improving outcomes for patients who have not responded adequately to existing therapies. As these biologics continue to evolve, ongoing education and training in their use will be essential for optimizing asthma management and improving patient outcomes in clinical practice.

Clinical Perspective

Workflow: Clinicians should consider eosinophil levels and exacerbation history when selecting biologics.

Economics: Understanding the cost-effectiveness of these treatments will be crucial for healthcare systems.

Patient Outcomes: Individualized treatment plans based on these findings can lead to better asthma control and improved quality of life.

Dr. Nikhil Chatterjee, Pulmonology

Biologics for Severe Asthma: Comparing Mepolizumab, Benralizumab, Dupilumab, Tezepelumab, and Depemokimab

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Pulmonology in your inbox.

Related Drug Updates

WHO Releases 2026 Smoking Cessation Guidelines: Cytisinicline vs Varenicline vs NRT vs Bupropion

Trimbow vs Trelegy: New Guidelines for Severe Asthma Management

Asthma Triple Inhaler Therapy: 2026 Guidelines on Trimbow, Trelegy, and Breztri for Severe Asthma Management

Verified HCP Portal